28 results about "Meningitides" patented technology

The present application provides a kind of protecting group B meningococcal infection outer membrane vesicle composition, the outer membrane vesicle composition is by lipopolysaccharide modified group B meningococcal outer membrane vesicle and the outer membrane vesicle of group B meningococcal bacterium expressing recombinant protein is composed.The outer membrane vesicle composition provided by the present application has better protective effect on group B meningococcal infection relative to single strain outer membrane vesicle, and is more suitable for use as vaccine.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and / or by reducing the quantity of an OMV component in each dose.

The present invention relates to compositions and methods for preventing and / or treating bacterial disease (e.g., disease caused by Neisseria spp. such as Neisseria gonorrhoeae or Neisseria meningitidis). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria spp and sensitizing Neisseria spp to antibiotic treatment.

The present invention relates to the field of protein engineering modification. Provided are a group B neisseria meningitides antigen fusion protein combination and the use thereof. The antigen fusion protein combination comprises an antigen fusion protein, the antigen fusion protein comprising two or more antigens or fragments thereof that are optionally selected from the following: (i) an fHbp antigen; (ii) an NHBA antigen; (iii) an NadA antigen; or (iv) a PorA loop. The designed antigen fusion protein can combine one or more different subtypes for administration, thereby producing more broad-spectrum immune effects, improving the stability of the antigens, simplifying the production process and reducing costs.

The present invention provides a fusion protein in which H factor binding is desiredly reduced, and in particular, the present invention provides an optimized manufacturing process for the fusion protein and formulations containing the fusion protein. The present invention provides an efficient platform process for producing effective vaccine formulations against Neisseria meningitidis that meet multiple criteria with improved immunogenicity, safety, stability and availability.

The invention discloses issatchenkia orientalis capable of efficiently synthesizing L-malic acid and application of the issatchenkia orientalis, and belongs to the technical field of biological engineering. In an existing gene edited yeast strain in a laboratory, endogenous lactic dehydrogenase IoLDH2 and IoLDH3 are over-expressed, endogenous IoLDH1 is knocked out, and lactic dehydrogenase EcD-LDH from escherichia coli and lactic dehydrogenase NmD-LDH from neisseria meningitidis are over-expressed. After fermentation for 72 h in a 5 L fermentation tank, the accumulation amount of L-malic acid reaches 296.27 g / L, the yield is 0.97 g / g, the production intensity is 4.11 g / L / h, and the by-product lactic acid is remarkably reduced from 23.56 g / L to 6.7 g / L and is reduced by 71.56%.

The invention relates to the field of protein engineering. The invention provides a group B meningococcus antigen fusion protein composition and application thereof, the group B meningococcus antigen fusion protein composition comprises an antigen fusion protein, and the antigen fusion protein comprises two or more than two antigens or fragments thereof optionally selected from the following antigens: (i) an fHbp antigen; (ii) an NHBA antigen; (iii) a NadA antigen; or (iv) a PorA loop region (loop). The designed antigen fusion protein can be applied in combination with one or more different subtypes, a broader-spectrum immune effect is generated, meanwhile, the stability of the antigen is improved, the production process is simplified, and the production cost is reduced.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

The present inventors have identified a combination vaccine for immunization against bacterial meningitis caused by multiple pathogens.

The present disclosure relates to monoclonal antibodies targeting a Neisseria meningitidis serogroup B (MenB) antigen and their use for in vitro assay of the potency of MenB antigen for the manufacture of vaccine for preventing meningococcal infection.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The disclosure relates to an immunogenic composition comprising a combination of Neisseria meningitidis serogroup B antigens, said combination comprising at least one factor H binding protein (fHBP) A and at least one factor H binding protein (fHBP) B, and an aluminum hydroxyphosphate (AlPO4) adjuvant, the AlPO4 adjuvant being selected as having a point of zero charge (PZC) below 5.

The invention discloses neisseria meningitidis recombinant protein and application thereof. In particular to a neisseria meningitidis recombinant protein, a preparation method thereof and application of the neisseria meningitidis recombinant protein in a vaccine composition, and the recombinant protein can induce a more efficient specific bactericidal antibody and can be used for preventing infection caused by a group B meningococcal strain.

The invention provides a drug-loaded group B neisseria meningitidis and a preparation method and application of a vaccine thereof. The preparation method comprises the following steps: (1) co-incubating attenuated group B neisseria meningitidis by using sulfonated NHS-biotin to obtain biotinylated attenuated group B neisseria meningitidis; (2) after the Pam3CSK4 and the MDP are respectively coupled with the BSA (bovine serum albumin), the Pam3CSK4 and the MDP are respectively coupled with the streptavidin, so that a Pam3CSK4-BSA-streptavidin conjugate and an MDP-BSA-streptavidin conjugate are obtained; and (3) carrying out mixed incubation on the biotinylated attenuated group B neisseria meningitidis, the Pam3CSK4-BSA-streptavidin conjugate and the MDP-streptavidin conjugate, so as to obtain the drug-loaded group B neisseria meningitidis. According to the invention, a remarkable synergistic interaction effect is generated in the aspect of an antigen stimulation effect, the defect of weak immunogenicity of attenuated group B neisseria meningitidis is overcome, and the application prospect is relatively good.

In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

The invention provides a method for purifying group C meningococcus capsular polysaccharide. The method comprises a rough preparation step and a refining step, wherein in the refining step, two-step elution purification or flow-through combined elution purification is adopted for refining. The refined capsular polysaccharide prepared by the invention meets part of quality standards required by pharmacopeia, and does not use organic solvents and toxic reagents, such as ethanol, phenol, acetone, cetyltrimethylammonium bromide (CTAB) and the like, so that the harm of the capsular polysaccharide to human bodies and the environment is avoided. The method provided by the invention also has the advantages of simple process steps, short process time consumption, reduced production cost, high safety and the like.

The invention discloses application of a composition containing sulodexide and ceftriaxone in preparation of a medicine for treating bacterial meningitis, and belongs to the technical field of biological medicines. According to the invention, it is found for the first time that sulodexide and ceftriaxone are combined to have the effect of preventing and / or treating bacterial meningitis; animal experiments prove that the composition containing sulodexide and ceftriaxone improves cognitive impairment of a patient with bacterial meningitis by improving encephaledema of the patient with bacterial meningitis, reduces brain tissue damage of the patient with bacterial meningitis, inhibits brain neuroinflammation of the patient with bacterial meningitis, improves cognitive impairment of the patient with bacterial meningitis, and has a remarkable curative effect. Therefore, bacterial meningitis is prevented and / or treated, a new thought is provided for preparing bacterial meningitis products, and the application prospect is wide.

The present invention relates to compositions and methods for preventing and / or treating bacterial disease (e.g., disease caused by Neisseria sp. such as Neisseria gonorrhoeae or Neisseria meningitidis). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria sp.

The invention belongs to the technical field of biology, and particularly relates to a neisseria meningitidis nucleic acid detection system, a detection method and application. The detection system comprises: a primer pair for detecting neisseria meningitidis nucleic acid based on isothermal amplification: a first primer and a second primer, the first primer being selected from SEQ ID NO: 2-6, the second primer being selected from SEQ ID NO: 7-11, the neisseria meningitidis nucleic acid containing a nucleotide sequence as shown in SEQ ID NO: 1; cas12a, crRNA, and a reporter probe; the crRNA nucleotide sequence is selected from SEQ ID NO: 12 to SEQ ID NO: 14. Through combination of RAA isothermal amplification and CRISPR-Cas12a fluorescence detection and system optimization, the problem that rapid on-site detection cannot be realized by an existing PCR technology is successfully solved, and the rapid, sensitive, specific and convenient effects are achieved.

Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.

The invention pertains to a genetically modified Neisseria bacterium comprising a lipopolysaccharide (LPS) having a lipid A moiety and a modified oligosaccharide core, wherein the modified oligosaccharide core comprises a first oligosaccharide chain coupled to heptose 1 and a second oligosaccharide chain coupled to heptose 2, wherein the first and second oligosaccharide chain comprise a lactose directly coupled to respectively heptose 1 and 2, thereby forming a Neisseria gonorrhoeae 2C7 epitope. The modified bacterium may express a further non-native N. gonorrhoeae antigen, such as MetQ, AniA or NspA. The modified Neisseria bacterium is not Neisseria gonorrhoeae. The bacterium is preferably Neisseria meningitidis, Neisseria lactamica or Neisseria cinerea. The invention further pertains to LPS and OMVs obtained from the genetically modified bacterium, as well as methods for producing said modified bacterium.

This invention discloses a NO donor-type antifungal compound, its preparation method, and its application. The compound is represented by general formula V. By introducing a nitric oxide (NO) donor fragment into an active azole antibacterial fragment, it achieves the effect of dose-dependent slow release of nitric oxide in the presence of a thiol-containing nucleophilic reagent in vitro. When applied to antifungal drugs, the above compound can inhibit fungal growth at low concentrations and has broad-spectrum antibacterial activity. It has a strong inhibitory effect on Candida albicans, Candida glabrata, and Cryptococcus neoformans, and is also effective against cryptococcal meningitis caused by invasive Cryptococcus neoformans.

Variant Neisserial surface protein A (NspA) with reduced binding to human factor H (FH) are provided. These variants are useful for eliciting antibodies that are bactericidal for at least one strain of N. meningitidis. Compositions comprising such proteins, and methods of use of such proteins are disclosed.

The present invention relates to peptides, fusion proteins and compositions for inducing an immune response against bacteria. The invention also relates to the treatment or prevention of infections by sepsis-inducing bacteria, and to the treatment and prevention of pathological conditions caused by such bacteria. Such pathological conditions include sepsis, pneumonia, meningitis, endocarditis, enterocolitis, urinary tract infection, soft tissue infection, gastrointestinal tract infection, bloodstream infection, encephalitis, premature delivery and dead delivery.

The invention belongs to the field of gene engineering, and particularly discloses a soluble recombinant diphtheria toxin mutant CRM197 protein and a preparation method thereof, and the specific steps are as follows: a codon-optimized diphtheria toxin mutant CRM197 coding sequence is connected to an expression vector pBAD-HisB, and inducible expression is performed in Escherichia coli BW25113; the diphtheria toxin mutant CRM197 is converted into soluble expression from inclusion body by adding a signal peptide sequence at the N terminal, and after fermentation optimization and multi-step purification, the protein purity reaches 95% or above, and the yield is 600 mg / L or above; the invention also provides a fusion protein containing the soluble recombinant diphtheria toxin mutant CRM197 and a group B meningococcus fHBP-V1 or fHBP-V2 fragment, and the fusion protein can be used for developing a group B meningococcus vaccine.

The invention relates to the technical field of immunity, and discloses a novel carrier protein and application thereof. A novel carrier protein is designed, the amino acid sequence of the novel carrier protein is shown as SEQ ID NO: 1, the novel carrier protein is obtained by coding nucleotide shown as SEQ ID NO: 2, the ACYW135 group meningococcus polysaccharide conjugate vaccine prepared by using the carrier protein has the characteristics of simplicity and high efficiency, and the prepared ACYW135 group meningococcus polysaccharide conjugate vaccine has a good effect.